Exact sciences stock

ET, right here on Finance. Exact Sciences (EXAS): Shares up here, at around 21. It developed Cologuar a screening test for the early detection of colorectal cancer and pre-cancer. Company insiders that own EXACT Sciences stock include D Scott Cowar Graham Peter Lidgar Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Maneesh Arora, Mark Stenhouse, Michael S Wyzga, Scott C Johnson and Thomas D Carey.

View Institutional Ownership Trends for EXACT Sciences. High High is the highest sales price the stock has achieved during the regular trading hours, the intra-day high. View EXAS revenue estimates and earnings estimates, as well as analyst recommendations.

But which of these stocks is the better pick for. Cash was getting tight as the company spent aggressively to commercialize its new colon cancer test. Add in some troubling words from a government agency and it is understandable why short-sellers were predicting doom. Profile EXACT Sciences MORE. It has an intellectual property, which protects its non invasive, molecular screening technology for the detection of colorectal cancer.

The company was founded on Febru. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. The scores are based on the trading styles of Value, Growth, and Momentum. The stock appeared to be hit hard by news that the Trump administration is attempting to. View the latest EXAS stock quote and chart on MSN Money.

Dive deeper with interactive charts and top stories of EXACT SCIENCES CORPORATION. View EXAS historial stock data and compare to other stocks and exchanges. Find out if EXAS is the best investment for you.

Start a 14-day free trial to Morningstar Premium to unlock our take on EXAS. Investing in securities products involves risk, including possible loss of principal. ST Invest is a wholly owned subsidiary of StockTwits, Inc. With stocks to buy, a consensus on the Street is hard to beat. Its core product is a noninvasive screening test, Cologuar which analyzes stool-based DNA samples to detect the precancerous and early stages of colorectal cancer.

Take a look at this chart of the last year, which has seen shares advance from $7. EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population.

Bullish means we think the stock price will move higher. Bearish means we think the stock price will move lower. Start making your PredictWallStreet stock market predictions today.

This potentially could be a rebound after the stock dropped approximately yesterday. Benzinga Newsdesk Thu, Oct. Yesterday, the shares gained 2. Health Technology Biotechnology. Our investment research resources are provided to help you make informed investment decisions.

By aggregating the opinions and predictions of our best trading systems (trading bots), we come up with a general prediction. Given the current short-term tren the stock is expected to fall -31. EXAS has develope and currently commercializes the Cologuard test, a non-invasive stool-based deoxyribonucleic acid screening test designed to detect DNA markers for colorectal cancer.